-
公开(公告)号：EP3607964A1
公开(公告)日：2020-02-12
申请号：EP19195239.9
申请日：2011-01-21
申请人： Sanofi
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Rao, Ercole , Dreyer, Matthias
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
-
2.发明公开Pharmaceutical composition for treating a metabolic syndrome 审中-公开Pharmazutische Zusammensetzung zur Behandlung eines代谢综合征
公开(公告)号：EP2460527A1
公开(公告)日：2012-06-06
申请号：EP11174543.6
申请日：2010-01-21
申请人： SANOFI
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Rao, Ercole , Dreyer, Matthias
CPC分类号： A61K38/1825 , A61K38/26 , A61K45/06 , C07K14/50 , C07K2319/30 , A61K2300/00
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
摘要翻译： 本发明涉及含有至少一种FGF-21（成纤维细胞生长因子21）化合物，至少一种GLP-1R（胰高血糖素样肽-1受体）激动剂和任选的至少一种抗糖尿病药物和/ 或至少一种DPP-4（二肽基肽酶-4）抑制剂，用于治疗至少一种代谢综合征和/或动脉粥样硬化，特别是糖尿病，血脂异常，肥胖症和/或脂肪酸。
-
公开(公告)号：EP2359843A1
公开(公告)日：2011-08-24
申请号：EP10305070.4
申请日：2010-01-21
申请人： SANOFI
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Ercole, Rao , Dreyer, Matthias
CPC分类号： A61K38/1825 , A61K38/26 , A61K45/06 , C07K14/50 , C07K2319/30 , A61K2300/00
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
-
公开(公告)号：EP3216459B1
公开(公告)日：2018-09-26
申请号：EP16205881.2
申请日：2011-01-21
申请人： SANOFI
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Rao, Ercole , Dreyer, Matthias
CPC分类号： A61K38/26 , A61K38/1825 , A61K45/06 , C07K14/50 , C07K2319/30 , A61K2300/00
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
-
公开(公告)号：EP3357503A1
公开(公告)日：2018-08-08
申请号：EP18162214.3
申请日：2011-01-21
申请人： Sanofi
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Rao, Ercole , Dreyer, Matthias
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
-
公开(公告)号：EP3357503B1
公开(公告)日：2019-10-30
申请号：EP18162214.3
申请日：2011-01-21
申请人： Sanofi
-
公开(公告)号：EP3216459A1
公开(公告)日：2017-09-13
申请号：EP16205881.2
申请日：2011-01-21
申请人： SANOFI
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Rao, Ercole , Dreyer, Matthias
CPC分类号： A61K38/1825 , A61K38/26 , A61K45/06 , C07K14/50 , C07K2319/30 , A61K2300/00
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
摘要翻译： 本发明涉及含有至少一种FGF-21（成纤维细胞生长因子21）化合物，至少一种GLP-1R（胰高血糖素样肽-1受体）激动剂和任选的至少一种抗糖尿病药物和/ 或至少一种DPP-4（二肽基肽酶-4）抑制剂用于治疗至少一种代谢综合征和/或动脉粥样硬化，特别是糖尿病，血脂异常，肥胖症和/或肥胖症。
-
公开(公告)号：EP2754449A1
公开(公告)日：2014-07-16
申请号：EP14163127.5
申请日：2011-01-21
申请人： SANOFI
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Rao, Ercole , Dreyer, Matthias
CPC分类号： A61K38/1825 , A61K38/26 , A61K45/06 , C07K14/50 , C07K2319/30 , A61K2300/00
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.008 秒)
